Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Adeline Torro"'
Autor:
Matthieu Lacroix, Laetitia K. Linares, Natalia Rueda-Rincon, Katarzyna Bloch, Michela Di Michele, Carlo De Blasio, Caroline Fau, Laurie Gayte, Emilie Blanchet, Aline Mairal, Rita Derua, Fernando Cardona, Diane Beuzelin, Jean-Sebastien Annicotte, Nelly Pirot, Adeline Torro, Francisco J. Tinahones, Florence Bernex, Justine Bertrand-Michel, Dominique Langin, Lluis Fajas, Johannes V. Swinnen, Laurent Le Cam
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
The p53 tumor suppressor is also a regulator of metabolism, but the mechanisms controlling p53-associated metabolic activities remain poorly understood. Here the authors report that the deletion of the multifunctional protein E4F1 is protective again
Externí odkaz:
https://doaj.org/article/00ec515c8ba444a682cea51127843aeb
Autor:
Diego Tosi, Esther Pérez-Gracia, Salima Atis, Nadia Vié, Eve Combès, Mélissa Gabanou, Christel Larbouret, Marta Jarlier, Caroline Mollevi, Adeline Torro, Maguy Del Rio, Pierre Martineau, Céline Gongora
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan. Methods Phosphokinome profiling with peptide arrays of
Externí odkaz:
https://doaj.org/article/331b86359be842c48cdcab8ae7113b70
Autor:
Nadia Vie, Mélissa Gabanou, Diego Tosi, Céline Gongora, Adeline Torro, Caroline Mollevi, Christel Larbouret, Pierre Martineau, Marta Jarlier, Eve Combes, Salima Atis, Esther Pérez-Gracia, Maguy Del Rio
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2018, 18 (1), pp.812. ⟨10.1186/s12885-018-4712-z⟩
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
BMC Cancer, BioMed Central, 2018, 18 (1), pp.812. ⟨10.1186/s12885-018-4712-z⟩
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Background The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan. Methods Phosphokinome profiling with peptide arrays of tumour sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::300acd6d3769cf4033d8c83ece339e38
https://www.hal.inserm.fr/inserm-01857784
https://www.hal.inserm.fr/inserm-01857784
Autor:
Bruno Robert, Nadia Vezzio-Vie, Thibault Mazard, Marta Jarlier, Annick Causse, Alexandre Evrard, Eric Assenat, Pierre Martineau, Céline Gongora, Wilhem Leconet, Maguy Del Rio, Joelle Simony, Adeline Torro, Marc Ychou
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2013, 12 (10), pp.2121-2134. ⟨10.1158/1535-7163.MCT-12-0966⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2013, 12 (10), pp.2121-2134. ⟨10.1158/1535-7163.MCT-12-0966⟩
Despite recent advances in the treatment of colorectal cancer (CRC), tumor resistance is a frequent cause of chemotherapy failure. Therefore, new treatment options are needed to improve survival of patients with irinotecan-refractory CRCs, particular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f760e8f98e8f4c16f6e537fe8903c4
https://hal.archives-ouvertes.fr/hal-02362679
https://hal.archives-ouvertes.fr/hal-02362679